Comprehensive assessment and outcomes of patients with chronic periaortitis


Yardimci G., Düzgün S. A., Farisogullari B., Bolek E., ELDEM F. G., Erden A., ...Daha Fazla

Clinical and Experimental Rheumatology, cilt.40, sa.4, ss.801-810, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.55563/clinexprheumatol/araba3
  • Dergi Adı: Clinical and Experimental Rheumatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.801-810
  • Anahtar Kelimeler: chronic periaortitis, idiopathic retroperitoneal fibrosis, IgG4-RD, vasculitis, rituximab
  • Gazi Üniversitesi Adresli: Hayır

Özet

© Copyright Clinical and Experimental Rheumatology 2022.Objective Chronic periaortitis (CP) is a less known but more frequently diagnosed fibro-inflammatory disorder, but we know little about it and data regarding follow-up and outcome are still very limited. This study aims to identify the clinicopathologic, laboratory, and radiologic features, as well as outcomes of CP patients. Methods Patients with CP from HUVAC database were included in the study. CP was diagnosed based on compatible imaging findings and histopathological evaluation (if available), in addition to clinical findings. Demographics, laboratory, clinical, and imaging data were retrospectively reviewed from medical records. Results A total of 51 (male/female:37/14) patients were included in the study. Median (IQR) age was 63 (53-69) years and follow-up duration was 40 (4-60) months. 32 of the patients were IgG4-related CP. The most common form of CP in our cohort was idiopathic retroperitoneal fibrosis (82%), followed by inflammatory abdominal aortic aneurysms (12%) and peri-aneurysmal retroperitoneal fibrosis (8%). 8 (15.6%) patients had thoracic periaortitis and 16 (31.6%) venous involvement. Cyclophosphamide (CYC) combined with steroids was the most preferred treatment modality (43%), followed by rituximab (RTX) (31.3%). Follow-up imaging was done after a median (IQR) of 7 (3-11) months, 30% of the patients were stable and 64.1% showed regression. A total of 18 (35.2%) had been taken off therapy at the last visit. Conclusion Idiopathic retroperitoneal fibrosis was the most frequent presentation, whereas 15.6% of patients had thoracic involvement. Venous involvement was also not uncommon. Optimal time for follow-up imaging was determined as 6–9 months. Steroids along with CYC/RTX had a favourable outcome in the treatment of these patients.